EUVIMEDEUVIMED entdecken
Crossref

Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria

Cliodhna Murray, Katie Ridge, Niall Conlon

European Journal of Dermatology · 2023

DOI: 10.1684/ejd.2023.4563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2023. Verfasst von Cliodhna Murray und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Chronic Urticaria, Anti-Allergic Agents, Urticaria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaAnti-Allergic AgentsUrticariaHumansOmalizumabCosts and Cost AnalysisChronic DiseaseTreatment Outcome

Substanzen

OmalizumabAnti-Allergic Agents

Zitieren

APA

Murray, C., Ridge, K., & Conlon, N. (2023). Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria. European Journal of Dermatology. https://doi.org/10.1684/ejd.2023.4563

Vancouver

Murray C, Ridge K, Conlon N. Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria. European Journal of Dermatology. 2023. doi:10.1684/ejd.2023.4563

BibTeX
@article{Murray2023,
  author = {Murray, Cliodhna and Ridge, Katie and Conlon, Niall},
  title = {Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria},
  journal = {European Journal of Dermatology},
  year = {2023},
  doi = {10.1684/ejd.2023.4563}
}
Kostenlos starten →